Evidence map›Paper›PMID 36316072›Full record

ArticleBMJ open2022

Canadian Anaphylaxis Network-Predicting Recurrence after Emergency Presentation for Allergic REaction (CAN-PREPARE): a prospective, cohort study protocol.

Waleed Alqurashi, Marcus Shaker, George A Wells, Gary Stephen Collins, Matthew Greenhawt, Janet A Curran, Roger Zemek, Suzanne Schuh, Anne Ellis, Jennifer Gerdts and 8 more

Registry-linked trialAbstract readClinical Trial Protocol
In one paragraph

Article in BMJ open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05135377 (Canadian Anaphylaxis Network- Predicting Recurrence After Emergency Presentation for Allergic REaction), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05135377 active not recruitingnot on this map

Canadian Anaphylaxis Network- Predicting Recurrence After Emergency Presentation for Allergic REaction

TypeobservationalSponsorWaleed AlqurashiRan2022 to 2025Enrolled1,682ConditionsAnaphylaxisArmsObservational
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Waleed AlqurashiDepartment of Pediatrics and Emergency Medicine, University of Ottawa Faculty of Medicine, Ottawa, Ontario, Canada walqurashi@cheo.on.ca.ORCID 0000-0001-9772-5291
Marcus ShakerSection of Allergy and Clinical Immunology, Children's Hospital at Dartmouth-Hitchcock, Lebanon, New Hampshire, USA.
George A WellsCardiovascular Research Methods Centre, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
Gary Stephen CollinsCentre for Statistics in Medicine, University of Oxford Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, Oxford, UK.ORCID 0000-0002-2772-2316
Matthew GreenhawtSection of Allergy and Clinical Immunology, Children's Hospital Colorado, Aurora, Colorado, USA.
Janet A CurranPediatrics, IWK Health Centre, Halifax, Nova Scotia, Canada.ORCID 0000-0001-9977-0467
Roger ZemekDepartment of Pediatrics and Emergency Medicine, University of Ottawa Faculty of Medicine, Ottawa, Ontario, Canada.ORCID 0000-0001-7807-2459
Suzanne SchuhPediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada.ORCID 0000-0001-7567-6919
Anne EllisDivision of Allergy and Immunology, Queen's University, Kingston, Ontario, Canada.
Jennifer GerdtsFood Allergy Canada, Toronto, Ontario, Canada.
Cheryl KreviazukChildren's Hospital of Eastern Ontario Research Institute, Ottawa, Ontario, Canada.ORCID 0000-0002-5778-6943
Andrew DixonDepartment of Pediatrics, University of Alberta, Edmonton, Alberta, Canada.ORCID 0000-0003-4722-3298
Mohamed EltorkiMcMaster Children's Hospital, Hamilton, Ontario, Canada.ORCID 0000-0001-6978-0015
Stephen B FreedmanDepartments of Pediatrics and Emergency Medicine, Alberta Children's Hospital, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada.ORCID 0000-0003-2319-6192
Jocelyn GravelCentre Hospitalier Universitaire Sainte-Justine, Universite de Montreal, Montreal, Québec, Canada.ORCID 0000-0001-5901-4990
Naveen PoonaiDepartments of Paediatrics, Internal Medicine, Epidemiology & Biostatistics, Western University, London, Ontario, Canada.ORCID 0000-0003-1540-0413
Margitta WormDivision of Allergy and Immunology, Department of Dermatology and Allergy, Charite Universitatsmedizin Berlin, Berlin, Germany.ORCID 0000-0002-3449-1245
Amy C PlintDepartment of Pediatrics and Emergency Medicine, University of Ottawa Faculty of Medicine, Ottawa, Ontario, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAnaphylaxis is a severe, potentially fatal multiorgan system manifestation of an allergic reaction. The highest incidence of anaphylaxis is in children and adolescents. Biphasic anaphylaxis (BA) is defined as the recurrence of allergic symptoms after resolution of an initial reaction. It has been reported to occur in 10%-20% of cases within 1-48 hours from the onset of the initial reaction. The dilemma for physicians is determining which patients with resolved anaphylaxis should be observed for BA and for how long. Guidelines for duration of postanaphylaxis monitoring vary, are based on limited evidence and can have unintended negative impacts on patient safety, quality of life and healthcare resources. The objectives of this study are to derive a prognostic model for BA and to develop a risk-scoring system that informs disposition decisions of children who present to emergency departments (ED) with anaphylaxis. METHODS AND ANALYSIS: This prospective multicentre cohort study will enrol 1682 patients from seven paediatric EDs that are members of the Paediatric Emergency Research Canada network. We will enrol patients younger than 18 years of age with an allergic reaction meeting anaphylaxis diagnostic criteria. Trained ED research assistants will screen, obtain consent and prospectively collect study data. Research assistants will follow patients during their ED visit and ascertain, in conjunction with the medical team, if the patient develops BA. A standardised follow-up survey conducted following study enrolment will determine if a biphasic reaction occurred after ED disposition. Model development will conform to the broad principles of the PROGRESS (Prognosis Research Strategy) framework and reporting will follow the Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis Statement. ETHICS AND DISSEMINATION: Ethics approval has been received from all participating centres. Our dissemination plan focuses on informing clinicians, policy makers and parents of the results through publication in peer-reviewed journals and broadcasting on multiple media platforms. TRIAL REGISTRATION NUMBER: NCT05135377.

Indexed as

AnaphylaxisAdolescentCanadaChildCohort StudiesEmergency Service, HospitalHumansMulticenter Studies as TopicProspective StudiesQuality of LifeEPIDEMIOLOGYPaediatric A&E and ambulatory carePAEDIATRICS

Identifiers

PMID36316072
PMCPMC9628530

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.